Alliance at ASCO 2016

The 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) will convene in Chicago June 3-7, bringing together more than 34,000 oncology professionals from around the world. This year's meeting theme, "Collective Wisdom: the Future of Patient-Centered Care and Research," focuses on the power of combining knowledge - across disciplines, disease sites, and treatment approaches - to evolve and shape the future of patient care and research. The theme encourages the exploration of advances in big data technology that are speeding up collective discovery and revealing new insights faster than ever before.

Each year, ASCO attendees learn from leading-edge scientific presentations, including papers and talks from Alliance researchers, as well as thousands of scientific abstracts and research news developments. At this year's conference, Alliance scientists will present more than 15 studies, sharing the latest findings on breast cancer, brain cancer, hematologic cancers, and gastric cancer, along with cancer control research.

Join the Twitter conversation at #ASCO16 and please include @ALLIANCE_org

Here's a snapshot of studies that Alliance researchers will be presenting:

**Breast Cancer-HER2/ER**

A genome-wide association study (GWAS) of progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503

Presenter: Federico Innocenti
Study #: 40503
Abstract # 538 | Hall A | Poster Session (Board #26) | Poster
June 5, 2016, 8 am to 11:30 am

**Breast Cancer-Triple-Negative/Cytotoxics/Local Therapy**

Accrual of older patients (pts) with breast cancer to Alliance systemic therapy trials over time: A151527

Presenter: Rachel A. Freedman
Study #: Alliance 151527
Abstract # 1024 | Poster Session (Board #129) | Oral Presentation
June 5, 2016, 8 am to 11:30 am | Hall A

Ten-year survival results of ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node (Alliance)

Presenter: Armando E. Giuliano
Study #: ACOSOG Z0011
Abstract # 1007 | Hall D2 | Oral Presentation
Central Nervous System Tumors

Validating RNAseq-signatures of vorinostat (VOR) sensitivity and resistance in patients with newly diagnosed glioblastoma (GBM) treated with VOR, temozolomide and radiation therapy in Alliance N0874/ABTC-0902
Presenter: S. Keith Anderson
Study #: NCCTG N0874/ABTC-0902
Abstract # 2029 | Hall A | Poster Session (Board#218) | Poster
June 4, 2016, 1 pm to 4:30 pm

Gastrointestinal (Colorectal) Cancer

Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or bev plus Cetux: Results from CALGB 80405 (Alliance)
Presenter: Andrew B. Nixon
Study #: CALGB 80405
Abstract # 3597 | Poster Session (Board #294) | Poster
June 4, 2016, 8 am to 11:30 am | Hall A

Association of tumor infiltrating lymphocytes (TILs) with molecular subtype and prognosis in stage III colon cancers (CC) from a FOLFOX-based adjuvant chemotherapy trial
Presenter: Frank A. Sinicrope
Study #: NCCTG N0147
Abstract # 3518 | Poster Discussion Session (Board #215) | Poster
June 4, 2016, 8 am to 11:30 am | Hall A

Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials
Presenter: Frank A. Sinicrope
Study #: NCCTG N0147
Abstract #: 3600 | Poster Discussion Session (Board #297) | Poster
June 4, 2016, 8 am to 11:30 am | Hall A

Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance)
Presenter: Alan P. Venook
Study #: CALGB 80405
Abstract # 3504 | Oral Presentation
June 5, 2016, 8 am to 11 am | Hall B1

Gastrointestinal (Noncolorectal) Cancer

Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)
Presenter: Ghassan K. Abou-Alfa
Study #: CALGB 80802
Abstract # 4003 | Oral Presentation
June 6, 2016, 8 am to 11 am | Hall B1

Hematologic Malignancies-Plasma Cell Dyscrasia
Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS)
Presenter: Michel Attal
Study #: CALGB 100104
Abstract # 8001 | Oral Presentation
June 3, 2016, 3 pm to 6 pm | Location: E354b

Patient and Survivor Care

Identifying risk factors for toxicity in patients (pts) with hormone-receptor positive (HR+) advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 (Alliance) correlative study
Presenter: Daneng Li
Study #: CALGB 40503
Abstract # 10047 | Poster
June 6, 2016, 1 pm to 4:30 pm | Hall A

Impact of age and comorbidity on treatment of non-small cell lung cancer (NSCLC) recurrence (AFT-03)
Presenter: Melisa L. Wong
Study #: AFT-03
Abstract # 10037 | Poster Session (Board #25)
June 6, 2016, 1 pm to 4:30 pm | Hall A

Sarcoma

A phase I/randomized phase II study of MLN0128 vs pazopanib in patients with locally advanced/unresectable and/or metastatic sarcoma: Alliance A091304
Presenter: William D. Tap
Study #: Alliance A091304
Abstract # TPS11073 | Poster Session (Board #197b) | Poster
June 6, 2016, 8 am to 11:30 am | Hall A

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2016 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Gastrointestinal (Colorectal) Cancer

Deletions in HSP110 T17 and patient prognosis in stage III microsatellite instable (MSI) colon cancers: Findings from CALGB
Presenter: Christina Sing-Ying Wu
Abstract # e15148 | Publication Only
Study #: CALGB 89803 / N0147

Health Services Research and Quality of Care

Detection and treatment of colorectal cancer (CRC) recurrence during routine surveillance: A nationwide cohort study
Presenter: Rebecca A Snyder
Abstract # e18137 | Publication Only
Study #: AFT-02

Association between patient perception of oncology clinical trial participation and survival: N0392 (Alliance)
ALLIANCE MEMBERS ON THE MOVE AT ASCO

Clifford A. Hudis, MD | Named Incoming CEO of ASCO
Learn more about Dr. Hudis’ new role in The Cancer Letter.

*The Atlantic’s The Search for Answers: Fighting Rare Cancers - Panel*
Alliance members - William D. Tap, MD; Jedd D. Wolchok, MD; and Richard L. Schilsky, MD - will participate in a panel discussion hosted by *The Atlantic* to examine how new strategies in the fight against rare cancer can revolutionize the treatment paradigm; how rare cancer communities are mobilizing at the grassroots level; and how the White House’s recently announced Moonshot initiative will impact cancer research. The event will be held in Chicago a day before ASCO begins on June 2. Take a look at the agenda.